PaxMedica, Inc. Common Stock (PXMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.71 Million USD | -172.55% |
| 2022 | -1.72 Million USD | -289.19% |
| 2021 | -444.08 Thousand USD | 13.26% |
| 2020 | -511.98 Thousand USD | -1952.29% |
| 2019 | -24.94 Thousand USD | -167.61% |
| 2018 | -9322.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.62 Million USD | 65.46% |
| 2024 Q2 | -324.48 Thousand USD | 80.05% |
| 2023 Q3 | 428.3 Thousand USD | 130.49% |
| 2023 Q1 | -2.44 Million USD | -41.48% |
| 2023 FY | -4.71 Million USD | -172.55% |
| 2023 Q2 | -1.4 Million USD | 42.55% |
| 2023 Q4 | -4.71 Million USD | -1199.83% |
| 2022 Q3 | -5.4 Million USD | -550.61% |
| 2022 Q4 | -1.72 Million USD | 68.03% |
| 2022 FY | -1.72 Million USD | -289.19% |
| 2022 Q1 | -49.38 Thousand USD | 88.88% |
| 2022 Q2 | 1.19 Million USD | 2529.77% |
| 2021 Q3 | -1.79 Million USD | 0.0% |
| 2021 FY | -444.08 Thousand USD | 13.26% |
| 2021 Q4 | -444.08 Thousand USD | 75.31% |
| 2020 Q2 | -26.86 Thousand USD | 89.25% |
| 2020 Q1 | -249.8 Thousand USD | 0.0% |
| 2020 FY | -511.98 Thousand USD | -1952.29% |
| 2020 Q4 | -511.98 Thousand USD | 0.0% |
| 2019 FY | -24.94 Thousand USD | -167.61% |
| 2018 FY | -9322.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 359.379% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -23.477% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 475.649% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 114.623% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -401.666% |
| Better Therapeutics, Inc. | -860 Thousand USD | -447.749% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 80.195% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 1534.243% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 203.078% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 19.103% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 247.3% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 248.756% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 194.175% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 103.514% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 2729.44% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 138.178% |
| Molecular Templates, Inc. | 707 Thousand USD | 766.286% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 1174.4% |
| NexImmune, Inc. | -3.13 Million USD | -50.325% |
| Orgenesis Inc. | 21.78 Million USD | 121.624% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 280.07% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -945812.048% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -3681.37% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 104.249% |
| Statera Biopharma, Inc. | 14.41 Million USD | 132.676% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 37.985% |
| Trevena, Inc. | 2.25 Million USD | 308.62% |
| Vaxxinity, Inc. | 10.13 Million USD | 146.493% |
| Vaccinex, Inc. | -1.28 Million USD | -265.733% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 1467.6% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 135.582% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 6646.013% |